• LAST PRICE
    1.4200
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.4000/ 10
  • Ask / Lots
    1.5100/ 3
  • Open / Previous Close
    --- / 1.4200
  • Day Range
    ---
  • 52 Week Range
    Low 1.2500
    High 3.3000
  • Volume
    4
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
Table Data Not Available
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesANEB
Anebulo Pharmaceuticals Inc
36.8M
-4.6x
---
United StatesALTS
ALT5 Sigma Corp
36.6M
-0.7x
---
United StatesRAPT
RAPT Therapeutics Inc
36.2M
-0.4x
---
United StatesHSTC
HST Global Inc
37.6M
-61.1x
---
United StatesFBRX
Forte Biosciences Inc
35.9M
-1.3x
---
United StatesLTRN
Lantern Pharma Inc
37.7M
-2.1x
---
As of 2024-12-06

Company Information

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous treatment. Selonabant has completed dosing in a Phase II clinical trial evaluating its utility in blocking and reversing the negative effects of acute cannabinoid intoxication. It is also prioritizing the advancement of a selonabant IV formulation as a potential treatment for pediatric patients with unintentional cannabis poisoning.

Contact Information

Headquarters
Jfl Capital Management 1017 Rr 620 S, Suite 107LAKEWAY, TX, United States 78734
Phone
512-598-0931
Fax
---

Executives

No data available

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$36.8M
Revenue (TTM)
$0.00
Shares Outstanding
25.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-1.10
EPS
$-0.31
Book Value
$0.15
P/E Ratio
-4.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.